Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;65(7):1414-1419.
doi: 10.1111/jgs.14795. Epub 2017 Mar 6.

Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy

Kerri M Winters-Stone  1   2 , Esther Moe  3 , Julie N Graff  1 , Nathan F Dieckmann  2 , Sydnee Stoyles  2 , Carolyn Borsch  2 , Joshi J Alumkal  1 , Christopher L Amling  1 , Tomasz M Beer  1
Affiliations

Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy

Kerri M Winters-Stone et al. J Am Geriatr Soc. 2017 Jul.

Abstract

Objectives: To compare the prevalence of and association between falls and frailty of prostate cancer survivors (PCSs) who were current, past or never users of androgen deprivation therapy (ADT).

Design: Cross-sectional.

Setting: Mail and electronic survey.

Participants: PCSs (N = 280; mean age 72 ± 8).

Measurements: Cancer history, falls, and frailty status (robust, prefrail, frail) using traditionally defined and obese phenotypes.

Results: Current (37%) or past (34%) ADT users were more than twice as likely to have fallen in the previous year as never users (15%) (P = .002). ADT users had twice as many recurrent falls (P < .001) and more fall-related injuries than unexposed men (P = .01). Current (43%) or past (40%) ADT users were more likely to be classified as prefrail or frail than never users (15%) (P < .001), and the prevalence of combined obese frailty + prefrailty was even greater in current (59%) or past (62%) ADT users than never users (25%) (P < .001). Traditional and obese frailty significantly increased the likelihood of reporting falls in the previous year (odds ratio (OR) = 2.15, 95% CI = 1.18-3.94 and OR = 2.97, 95% CI = 1.62-5.58, respectively) and was also associated with greater risk of recurrent falls (OR = 3.10, 95% CI = 1.48-6.5 and OR = 3.99, 95% CI = 1.79-8.89, respectively).

Conclusions: Current and past exposure to ADT is linked to higher risk of falls and frailty than no treatment. PCSs should be appropriately counseled on fall prevention strategies, and approaches to reduce frailty should be considered.

Keywords: androgens; falls; frailty; prostate cancer; survivorship.

PubMed Disclaimer

References

    1. American Cancer Society. Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 2015. p. 54.
    1. Connolly RM, Carducci MA, Antonarakis ES. Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl. 2012;14:177–186. - PMC - PubMed
    1. Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W. Obese Frailty, Physical Performance Deficits, and Falls in Older Men with Biochemical Recurrence of Prostate Cancer on Androgen Deprivation Therapy: A Case-control Study. Urology. 2011;77:934–940. - PMC - PubMed
    1. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197. - PubMed
    1. Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. Journal of Clinical Oncology. 2016;34:2098–2106. - PubMed

Substances